Storage, Distribution and Display of Medical Devices in Nigeria: Article 11 and GDP

1. Key takeaways

Nigeria’s requirements for storage, distribution and display are set out in Article 11: devices must be stored, distributed or displayed in accordance with the conditions stated on their approved label and in accordance with the NAFDAC good distribution practice (GDP Regulations).

The provision contains two anchors: one is the conditions stated on the approved label (which are product-specific, originating from your own registration dossier); the other is the official good distribution practice (which is general, applying to all operators). Both must be satisfied; neither can substitute for the other. A warehouse that meets GDP in general terms still violates Article 11 if it fails the label conditions of a particular device, and vice versa.

2. Legal basis

3. Expert insights

Insight one: Article 11 turns label conditions into enforceable legal obligations.

Storage conditions on the label (which Article 22 requires to be stated) are usually phrases such as 2–8 °C, protect from light, or store in a dry place. The effect of Article 11 is that once these words are approved, they become conditions that the storage, distribution and display stages must observe. A warehouse temperature excursion is not merely improper handling; it is a breach of approved conditions, which can fall under Article 8(1)(b) (contravention of registration conditions) or Article 8(1)(e) (premises non-compliance with GDP / GWP). The label, in other words, is not marketing text — it is a binding operating specification.

Insight two: the duty holders extend to display — hospitals and pharmacies are within scope.

The three actions listed in Article 11 are stored, distributed or displayed. Display means that end-point presentation is also constrained — including pharmacy shelves, hospital storerooms and exhibition stands. When exhibiting in Nigeria, the display conditions for samples must equally comply with the approved label. Trade-show logistics teams rarely read regulatory texts, so this requirement needs to be written into event checklists rather than assumed.

Insight three: cold-chain devices carry the highest risk, because Article 11 connects directly to Article 8(1)(e).

Article 8(1)(e) expressly lists GWP (good warehousing practice) among premises compliance requirements. For IVD reagents and cold-chain consumables, Nigeria’s power supply and transport conditions pose a real challenge to the cold chain. When selecting local partners, cold-chain validation (data loggers, power-failure contingency plans, transport validation) should be an entry condition, not a bonus item. The cost of that validation is trivial compared with the cost of a destroyed batch or a suspension inquiry.

Insight four: the 2025 draft plans a dedicated Part 7 (§79–§90); the direction is greater detail.

The 2025 draft builds a dedicated part on good storage and distribution using 12 provisions (§79–§90). This does not create new obligations; it concretises the general requirements of Article 11. The draft is not yet gazetted, but the direction is clear: Nigeria is upgrading GDP/GWP from referenced norms into device-specific statutory text. Reserve a slot in the 2026 compliance calendar for preparing the implementation materials this will require.

Insight five: storage and distribution records are the foundation of recall and vigilance.

The react element of the PMS system in Article 12(2) and the recall progress monitoring in PMS-GDL-020-00 both depend on distribution records. Storage and distribution are not merely a logistics matter; they are the starting point of the evidence chain for post-market compliance. Every recall completion rate ever reported to an agency was computed from these records, and incomplete records convert a manageable recall into an uncloseable one.

4. Practical recommendations

1. Write the approved label storage conditions into warehousing and transport SOPs, with excursion alarms and disposition procedures.
2. Include GDP / GWP compliance and cold-chain validation in local partner entry criteria, with periodic re-review (Article 8(1)(e)).
3. Bring exhibitions and end-point displays into the compliance inspection scope, not only warehouses (Article 11).
4. Equip cold-chain products with data loggers and power-failure contingency plans, and temperature-validate transport routes.
5. Keep distribution records complete and traceable to support recall progress monitoring.
6. Track the gazettal progress of draft §79–§90 of 2025 and prepare the detailed implementation materials in advance.

5. Verification checklist

• □ Warehousing and transport SOPs incorporate the storage conditions stated on the approved label (Articles 11, 22).
• □ Local partners have passed a GDP / GWP compliance review (Article 8(1)(e)).
• □ Cold-chain products are equipped with data loggers, power-failure contingency plans and transport validation.
• □ Display settings (pharmacies, hospital storerooms, exhibition stands) are included in compliance inspections.
• □ Distribution records are complete and can support recall progress monitoring.
• □ A gazettal tracking mechanism for draft §79–§90 of 2025 has been established.

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC Regulations text (S.I. No. 42 of 2024, Articles 8(1)(b)(e), 11, 22) and the GMP Guidelines (DER-GDL-025-00 §13.1, §13.2); the specific provisions of the GDP Regulations are subject to the current NAFDAC text; Part 7 (§79–§90) of the 2025 draft was published on 23 July 2025 and is not yet gazetted, and is referenced only as an indication of regulatory direction.

• Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
• Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
• Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.